Repro Med Systems, Inc. (NASDAQ:KRMD) – Equities research analysts at Piper Sandler decreased their Q4 2021 EPS estimates for Repro Med Systems in a research report issued on Wednesday, May 12th. Piper Sandler analyst M. O’brien now expects that the company will earn ($0.01) per share for the quarter, down from their prior estimate of $0.01. Piper Sandler currently has a “Neutral” rating and a $3.50 target price on the stock. Piper Sandler also issued estimates for Repro Med Systems’ Q2 2022 earnings at ($0.01) EPS, Q3 2022 earnings at ($0.01) EPS and Q4 2022 earnings at $0.00 EPS.
Repro Med Systems (NASDAQ:KRMD) last posted its quarterly earnings results on Monday, March 22nd. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.03). Repro Med Systems had a positive return on equity of 6.79% and a negative net margin of 1.74%. The business had revenue of $4.06 million during the quarter.
Shares of KRMD stock opened at $4.10 on Friday. Repro Med Systems has a 52-week low of $2.70 and a 52-week high of $11.36. The stock has a market cap of $182.35 million, a PE ratio of -410.00 and a beta of 0.30. The firm’s 50 day moving average price is $3.46 and its two-hundred day moving average price is $4.46.
Several large investors have recently modified their holdings of KRMD. Alpha Paradigm Partners LLC increased its position in Repro Med Systems by 4.8% during the 1st quarter. Alpha Paradigm Partners LLC now owns 62,473 shares of the company’s stock worth $220,000 after purchasing an additional 2,860 shares in the last quarter. PEAK6 Investments LLC bought a new stake in shares of Repro Med Systems in the 1st quarter valued at $179,000. Renaissance Technologies LLC boosted its stake in shares of Repro Med Systems by 658.5% in the 1st quarter. Renaissance Technologies LLC now owns 152,800 shares of the company’s stock valued at $538,000 after purchasing an additional 132,656 shares during the last quarter. Geode Capital Management LLC boosted its stake in Repro Med Systems by 20.7% during the first quarter. Geode Capital Management LLC now owns 452,946 shares of the company’s stock worth $1,594,000 after acquiring an additional 77,775 shares in the last quarter. Finally, Acuitas Investments LLC boosted its stake in Repro Med Systems by 16.1% during the first quarter. Acuitas Investments LLC now owns 166,839 shares of the company’s stock worth $587,000 after acquiring an additional 23,134 shares in the last quarter. Institutional investors own 65.37% of the company’s stock.
Repro Med Systems Company Profile
Repro Med Systems, Inc, doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing.
Featured Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Repro Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.